Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Implementation and Evaluation of Pre-treatment DPYD genotyping for dose individualization of fluoropyrimidine therapy
EF 2021-22
Résumé
Fluoropyrimidines are commonly prescribed anti-cancer drugs but they cause severe adverse drug reactions in up to a third of patients. The same dose of one drug may be efficacious and safe in one person but cause a severe adverse drug reaction in another. Genetic variation is a key factor that influences the occurrence of serious adverse drug reactions. In the case of fluoropyrimidines, 3-8% of the western population has genetic variation in the gene DPYD that puts them at over 70% risk for severe fluoropyrimidine adverse drug reactions. These people can often be safely treated with lower fluoropyrimidine doses. The goal of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) is to implement testing of genetic markers to predict the risk of adverse drug reactions. Therefore, I aim to use the resources of CPNDS to implementDPYD genetic testing at BC Cancer Agency, where people who test positive receive a reduced dose of fluoropyrimidines to prevent severe adverse drug reactions. This is highly relevant for a patients quality of life because adverse drug reactions result in hospitalizations and discontinuation of anti-cancer treatments. I will evaluate theDPYDtesting program by analyzing the extent fluoropyrimidine adverse drug reactions and related care are reduced after the program.Additionally, I aim to develop an analytical plan for identifying novel genetic variants associated with fluoropyrimidine adverse drug reactions with the genetic material collected in this study. Using genetics to reduce the risk of adverse drug reactions and inform treatment decisions is an essential part of precision medicine and will improve health outcomes for Canadians, as well as the 2 million patients per year all around the world who use fluoropyrimidines.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466643
Name
Wu Angela
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Implementation and Evaluation of Pre-treatment DPYD genotyping for dose individualization of fluoropyrimidine therapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions; Genetic Testing; Oncology; Pharmacogenomics; Precision Medicine
Abstract
Fluoropyrimidines are commonly prescribed anti-cancer drugs but they cause severe adverse drug reactions in up to a third of patients. The same dose of one drug may be efficacious and safe in one person but cause a severe adverse drug reaction in another. Genetic variation is a key factor that influences the occurrence of serious adverse drug reactions. In the case of fluoropyrimidines, 3-8% of the western population has genetic variation in the gene DPYD that puts them at over 70% risk for severe fluoropyrimidine adverse drug reactions. These people can often be safely treated with lower fluoropyrimidine doses. The goal of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) is to implement testing of genetic markers to predict the risk of adverse drug reactions. Therefore, I aim to use the resources of CPNDS to implementDPYD genetic testing at BC Cancer Agency, where people who test positive receive a reduced dose of fluoropyrimidines to prevent severe adverse drug reactions. This is highly relevant for a patients quality of life because adverse drug reactions result in hospitalizations and discontinuation of anti-cancer treatments. I will evaluate theDPYDtesting program by analyzing the extent fluoropyrimidine adverse drug reactions and related care are reduced after the program.Additionally, I aim to develop an analytical plan for identifying novel genetic variants associated with fluoropyrimidine adverse drug reactions with the genetic material collected in this study. Using genetics to reduce the risk of adverse drug reactions and inform treatment decisions is an essential part of precision medicine and will improve health outcomes for Canadians, as well as the 2 million patients per year all around the world who use fluoropyrimidines.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wu, Angela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~